|Articles|May 1, 2001
- Pharmaceutical Executive-05-01-2001
- Volume 0
- Issue 0
The Next Y2K
Author(s)Mark E. Kolb
Companies Face Costly System Overhauls With New FDA Regulations
Advertisement
Articles in this issue
over 24 years ago
Policy: Task Mastersover 24 years ago
Pharmacia's Carrie Cox: HBA Woman of the Yearover 24 years ago
Friends of Complexityover 24 years ago
Under Federal Fireover 24 years ago
Task Force: Enter the Fixersover 24 years ago
Political ScienceNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
